Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Oviedo
Original Assignee
Universidad de Oviedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de OviedofiledCriticalUniversidad de Oviedo
Priority to ES9400265ApriorityCriticalpatent/ES2088820B1/es
Priority to PCT/ES1994/000135prioritypatent/WO1995016711A1/es
Priority to EP95903822Aprioritypatent/EP0687688A1/en
Publication of ES2088820A1publicationCriticalpatent/ES2088820A1/es
Application grantedgrantedCritical
Publication of ES2088820B1publicationCriticalpatent/ES2088820B1/es
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
ANTICUERPOS MONOCLONALES ANTINEUMOLISINA. SE SUMINISTRAN HIBRIDOMAS ESTABLES MONOCLONALES ESPECIFICOS PARA LA NEUMOLISINA QUE: 1) RECONOCEN EPITOPOS DISTINTOS EN LA MOLECULA DE NEUMOLISINA; Y 2) NEUTRALIZAN SU ACCION HEMOLITICA IN VITRO. ESTOS ANTICUERPOS, FRAGMENTOS DERIVADOS DE ELLOS O FORMAS MODIFICADAS DE TODOS ELLOS, TIENEN APLICACIONES DIVERSAS, INCLUYENDO LAS DIAGNOSTICAS, PROFILACTICAS Y/O TERAPEUTICAS.
ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ